A Retrospective study to evaluate the efficacy and safety of short-term Ipilimumab directly followed by Nivolumab or Pembrolizumab in patients with advanced Melanoma
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 09 Dec 2016 New trial record
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress